| CAS NO: | 925206-65-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 268.02 |
|---|---|
| Formula | C5H6BrN3O5 |
| CAS No. | 925206-65-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 53 mg/mL (197.7 mM) |
| Water: <1 mg/mL | |
| Ethanol: 23 mg/mL (85.8 mM) | |
| Other info | Chemical Name: 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone InChi Key: JODKFOVZURLVTG-UHFFFAOYSA-N InChi Code: InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2 SMILES Code: O=[N+](C1([N+]([O-])=O)CN(C(CBr)=O)C1)[O-] |
| Synonyms | RRX-001; RRX 001; RRx001; ABDNAZ |
| In Vitro | In vitro activity: RRx-001 is a novel, systemically non-toxic, epigenetic anticancer agent for multiple tumour types, with activity mediated through increased nitric oxide (NO) production and PPP inhibition. Kinase Assay: RRx-001 is a potent inhibitor of G6PD. RRx-001 shows potent antimalarial, although as a single agent, the drug sensitivity testing indicated that higher dose of RRx-001 was required to inhibited 50 % of the parasite's activity (IC50 = 0.14 ± 0.04 ug/ml). |
|---|---|
| In Vivo | RRx-001 is a novel, nonexplosive molecule modified from a class of solid rocket propellants, has shown promise as a novel cancer therapeutic agent in a number of cell lines and tumor models. In mouse models, RRx-001 administered intravenously as a single agent was equipotent to cisplatin while better tolerated. RRx-001 also showed activity as a radiosensitizer in both in vitro and in vivo models. The activity of RRx-001 is thought to be associated with a nucleophilic substitution by circulating thiol compounds and covalent binding of RRx-001 to cysteinyl residues in Hb, followed by the generation of nitrogen oxides. |
| Animal model | CB-17 SCID-mice |
| Formulation & Dosage | 5 mg/kg or 10 mg/kg; i.v. |
| References | Malar J. 2015 May 28;14:218; Drug Metab Dispos. 2012 Sep;40(9):1810-6; Leukemia. 2016 Nov;30(11):2187-2197. |
m.cnreagent.com